It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Robert Aiken, MD

Patient Feedback
Specialty:
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Associate Professor
Medical or Graduate Education: Wayne State University School of Medicine
Residency: Baylor College of Medicine - Internal Medicine
  Neurological Institute of New York, Columbia University - Neurology
Fellowship: Memorial Sloan-Kettering Cancer Center - Neuro-Oncology
Clinical Expertise:
  • Brain tumor
  • Meningioma
  • Neuro-oncology
Research Interests:
  • Clinical trials of therapies for brain tumors
  • Developmental therapeutics
  • Evaluation of novel agents for treatment of brain tumors
  • Developmental cancer therapeutics
  • Early translational therapeutics
Google Map
  • University Neurologists
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 1010
  • Chicago, IL  60612
  • Phone: (312) 563-3452
  • Fax: (312) 942-1783
  • View Larger MapDriving Directions

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Primary brain tumors: introduction.
    Aiken RD, Byrne RW
    Semin. Oncol.
    2014 Aug
    41(4):437.
  2. Molecular neuro-oncology and the challenge of the blood-brain barrier.
    Aiken R
    Semin. Oncol.
    2014 Aug
    41(4):438-45.
  3. Erratum to: Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
    Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL.
    J Neurooncol. 2013
    2013 May
    113(1):151. doi: 10.1007/s11060-013-1118-2. No abstract available.
  4. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
    Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olsen JJ, Evans BA, Jensen RL.
    J Neurooncol. 2012
    2012 Nov
    110(2):257-64. doi: 10.1007/s11060-012-0964-7. Epub 2012 Aug 30.
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Friendliness/courtesy of the care provider
4.8
Explanations the care provider gave you about your problem or condition
4.8
Concern the care provider showed for your questions or worries
4.8
Likelihood of your recommending this care provider to others
4.7
Care provider's efforts to include you in decisions about your treatment
4.7
Information the care provider gave you about medications
4.6
Instructions the care provider gave you about follow-up care
4.7
Your confidence in this care provider
4.7
Degree to which care provider talked with you using words you could understand
4.7
Amount of time the care provider spent with you
4.7
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.